Drug Addiction - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：115頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Drug Addiction - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Drug Addiction - Pipeline Review, H1 2014’, provides an overview of the Drug Addiction’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Drug Addiction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Drug Addiction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Drug Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Drug Addiction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Drug Addiction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Drug Addiction - Pipeline Review, H1 2014’, provides an overview of the Drug Addiction’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Drug Addiction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Drug Addiction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Drug Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Drug Addiction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Drug Addiction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Drug Addiction Overview 10
Therapeutics Development 11
Pipeline Products for Drug Addiction - Overview 11
Pipeline Products for Drug Addiction - Comparative Analysis 12
Drug Addiction - Therapeutics under Development by Companies 13
Drug Addiction - Therapeutics under Investigation by Universities/Institutes 15
Drug Addiction - Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Drug Addiction - Products under Development by Companies 20
Drug Addiction - Products under Investigation by Universities/Institutes 21
Drug Addiction - Companies Involved in Therapeutics Development 22
Alkermes Plc 22
Aphios Corporation 23
Teva Pharmaceutical Industries Limited 24
Addex Therapeutics 25
Biotie Therapies Corp. 26
Camurus AB 27
Curemark, LLC 28
Omeros Corporation 29
Immunovaccine, Inc. 30
Kyorin Pharmaceutical Co., Ltd. 31
D&A Pharma SAS 32
Embera NeuroTherapeutics, Inc. 33
Lightlake Therapeutics Inc. 34
Rottapharm|Madaus 35
SK Biopharmaceuticals Co., Ltd. 36
LondonPharma Ltd 37
Savant HWP, Inc. 38
Drug Addiction - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 44
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
nepicastat hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ibudilast - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
buprenorphine hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
SKL-N05 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Butyrylcholinesterase - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
candesartan cilexetil - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
baclofen ER - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ketamine hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
(oxazepam + metyrapone) - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
(samidorphan + buprenorphine hydrochloride) - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
LT-22 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ASB - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
methadone - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
dronabinol - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ADX-88178 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ADX-71441 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
OMS-527 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Vaccine For Cocaine Addiction - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Cocaine Addiction Vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
MH-6 Vaccine - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MH-2 [R] Vaccine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Ibogaine Analog - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
5HT2 Modulators for CNS and Metabolic Disorders - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
CM-1212 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
methoxycoronaridine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ICKLH-SMO9 Vaccine - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
N-acetylcystein + MGluR5 Antagonist - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
CR-5542 Series - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Triazole Compounds - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecule to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecule to Activate Kappa Opioid Receptor for Central Nervous System - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecule to Inhibit Kappa Opioid Receptor for Central Nervous System - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Drug for Dependence - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Drug Addiction - Recent Pipeline Updates 89
Drug Addiction - Dormant Projects 102
Drug Addiction - Discontinued Products 103
Drug Addiction - Product Development Milestones 104
Featured News & Press Releases 104
Aug 09, 2013: Curemark wins patent for CM-1212 to treat drug, alcohol addiction 104
Jun 18, 2013: MediciNova Announces Presentation Of Preliminary Results From Phase Ib Study Of MN-166 In Methamphetamine Addiction At 75th Annual Meeting Of CPDD 104
May 10, 2013: Biotie Starts Phase II Clinical Study With Nepicastat In Cocaine Dependence 105
May 06, 2013: Scripps Scientists Report Preclinical Study Results Of Heroin Vaccine 106
Feb 25, 2013: MediciNova's MN-166 Receives Fast Track Designation From FDA For Treatment Of Methamphetamine Dependence 107
Feb 12, 2013: Collegium Pharma Announces Notice Of Allowance For US Patent Covering Oxycodone DETERx Extended-release Opioid Product 108
Jan 03, 2013: MediciNova Provides Development Update On MN-166 109
Nov 08, 2012: Catalyst Pharma Announces Top-Line Results Of CPP-109 Phase IIb Trial For Cocaine Addiction 110
Nov 01, 2012: Scripps Research Announces Promising Results In Early Tests Of Meth Vaccine 110
Sep 04, 2012: NIH Funds UCLA Phase II Study Of MediciNova's MN-166 For Treament Of Methamphetamine Addiction 111
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 115
Disclaimer 115
List of Tables
Number of Products under Development for Drug Addiction, H1 2014 11
Number of Products under Development for Drug Addiction - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Comparative Analysis by Unknown Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Investigation by Universities/Institutes, H1 2014 21
Drug Addiction - Pipeline by Alkermes Plc, H1 2014 22
Drug Addiction - Pipeline by Aphios Corporation, H1 2014 23
Drug Addiction - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 24
Drug Addiction - Pipeline by Addex Therapeutics, H1 2014 25
Drug Addiction - Pipeline by Biotie Therapies Corp., H1 2014 26
Drug Addiction - Pipeline by Camurus AB, H1 2014 27
Drug Addiction - Pipeline by Curemark, LLC, H1 2014 28
Drug Addiction - Pipeline by Omeros Corporation, H1 2014 29
Drug Addiction - Pipeline by Immunovaccine, Inc., H1 2014 30
Drug Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2014 31
Drug Addiction - Pipeline by D&A Pharma SAS, H1 2014 32
Drug Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H1 2014 33
Drug Addiction - Pipeline by Lightlake Therapeutics Inc., H1 2014 34
Drug Addiction - Pipeline by Rottapharm|Madaus, H1 2014 35
Drug Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 36
Drug Addiction - Pipeline by LondonPharma Ltd, H1 2014 37
Drug Addiction - Pipeline by Savant HWP, Inc., H1 2014 38
Assessment by Monotherapy Products, H1 2014 39
Assessment by Combination Products, H1 2014 40
Number of Products by Stage and Target, H1 2014 43
Number of Products by Stage and Mechanism of Action, H1 2014 46
Number of Products by Stage and Route of Administration, H1 2014 48
Number of Products by Stage and Molecule Type, H1 2014 50
Drug Addiction Therapeutics - Recent Pipeline Updates, H1 2014 89
Drug Addiction - Dormant Projects, H1 2014 102
Drug Addiction - Discontinued Products, H1 2014 103
List of Figures
Number of Products under Development for Drug Addiction, H1 2014 11
Number of Products under Development for Drug Addiction - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 39
Assessment by Combination Products, H1 2014 40
Number of Products by Top 10 Target, H1 2014 41
Number of Products by Stage and Top 10 Target, H1 2014 42
Number of Products by Top 10 Mechanism of Action, H1 2014 44
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 45
Number of Products by Top 10 Route of Administration, H1 2014 47
Number of Products by Stage and Top 10 Route of Administration, H1 2014 48
Number of Products by Top 10 Molecule Type, H1 2014 49
Number of Products by Stage and Top 10 Molecule Type, H1 2014 50
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Drug Addiction Overview 10
Therapeutics Development 11
Pipeline Products for Drug Addiction - Overview 11
Pipeline Products for Drug Addiction - Comparative Analysis 12
Drug Addiction - Therapeutics under Development by Companies 13
Drug Addiction - Therapeutics under Investigation by Universities/Institutes 15
Drug Addiction - Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Drug Addiction - Products under Development by Companies 20
Drug Addiction - Products under Investigation by Universities/Institutes 21
Drug Addiction - Companies Involved in Therapeutics Development 22
Alkermes Plc 22
Aphios Corporation 23
Teva Pharmaceutical Industries Limited 24
Addex Therapeutics 25
Biotie Therapies Corp. 26
Camurus AB 27
Curemark, LLC 28
Omeros Corporation 29
Immunovaccine, Inc. 30
Kyorin Pharmaceutical Co., Ltd. 31
D&A Pharma SAS 32
Embera NeuroTherapeutics, Inc. 33
Lightlake Therapeutics Inc. 34
Rottapharm|Madaus 35
SK Biopharmaceuticals Co., Ltd. 36
LondonPharma Ltd 37
Savant HWP, Inc. 38
Drug Addiction - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 44
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
nepicastat hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ibudilast - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
buprenorphine hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
SKL-N05 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Butyrylcholinesterase - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
candesartan cilexetil - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
baclofen ER - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ketamine hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
(oxazepam + metyrapone) - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
(samidorphan + buprenorphine hydrochloride) - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
LT-22 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ASB - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
methadone - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
dronabinol - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ADX-88178 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ADX-71441 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
OMS-527 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Vaccine For Cocaine Addiction - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Cocaine Addiction Vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
MH-6 Vaccine - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MH-2 [R] Vaccine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Ibogaine Analog - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
5HT2 Modulators for CNS and Metabolic Disorders - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
CM-1212 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
methoxycoronaridine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ICKLH-SMO9 Vaccine - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
N-acetylcystein + MGluR5 Antagonist - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
CR-5542 Series - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Triazole Compounds - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecule to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecule to Activate Kappa Opioid Receptor for Central Nervous System - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecule to Inhibit Kappa Opioid Receptor for Central Nervous System - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Drug for Dependence - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Drug Addiction - Recent Pipeline Updates 89
Drug Addiction - Dormant Projects 102
Drug Addiction - Discontinued Products 103
Drug Addiction - Product Development Milestones 104
Featured News & Press Releases 104
Aug 09, 2013: Curemark wins patent for CM-1212 to treat drug, alcohol addiction 104
Jun 18, 2013: MediciNova Announces Presentation Of Preliminary Results From Phase Ib Study Of MN-166 In Methamphetamine Addiction At 75th Annual Meeting Of CPDD 104
May 10, 2013: Biotie Starts Phase II Clinical Study With Nepicastat In Cocaine Dependence 105
May 06, 2013: Scripps Scientists Report Preclinical Study Results Of Heroin Vaccine 106
Feb 25, 2013: MediciNova's MN-166 Receives Fast Track Designation From FDA For Treatment Of Methamphetamine Dependence 107
Feb 12, 2013: Collegium Pharma Announces Notice Of Allowance For US Patent Covering Oxycodone DETERx Extended-release Opioid Product 108
Jan 03, 2013: MediciNova Provides Development Update On MN-166 109
Nov 08, 2012: Catalyst Pharma Announces Top-Line Results Of CPP-109 Phase IIb Trial For Cocaine Addiction 110
Nov 01, 2012: Scripps Research Announces Promising Results In Early Tests Of Meth Vaccine 110
Sep 04, 2012: NIH Funds UCLA Phase II Study Of MediciNova's MN-166 For Treament Of Methamphetamine Addiction 111
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 115
Disclaimer 115
List of Tables
Number of Products under Development for Drug Addiction, H1 2014 11
Number of Products under Development for Drug Addiction - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Comparative Analysis by Unknown Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Investigation by Universities/Institutes, H1 2014 21
Drug Addiction - Pipeline by Alkermes Plc, H1 2014 22
Drug Addiction - Pipeline by Aphios Corporation, H1 2014 23
Drug Addiction - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 24
Drug Addiction - Pipeline by Addex Therapeutics, H1 2014 25
Drug Addiction - Pipeline by Biotie Therapies Corp., H1 2014 26
Drug Addiction - Pipeline by Camurus AB, H1 2014 27
Drug Addiction - Pipeline by Curemark, LLC, H1 2014 28
Drug Addiction - Pipeline by Omeros Corporation, H1 2014 29
Drug Addiction - Pipeline by Immunovaccine, Inc., H1 2014 30
Drug Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2014 31
Drug Addiction - Pipeline by D&A Pharma SAS, H1 2014 32
Drug Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H1 2014 33
Drug Addiction - Pipeline by Lightlake Therapeutics Inc., H1 2014 34
Drug Addiction - Pipeline by Rottapharm|Madaus, H1 2014 35
Drug Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 36
Drug Addiction - Pipeline by LondonPharma Ltd, H1 2014 37
Drug Addiction - Pipeline by Savant HWP, Inc., H1 2014 38
Assessment by Monotherapy Products, H1 2014 39
Assessment by Combination Products, H1 2014 40
Number of Products by Stage and Target, H1 2014 43
Number of Products by Stage and Mechanism of Action, H1 2014 46
Number of Products by Stage and Route of Administration, H1 2014 48
Number of Products by Stage and Molecule Type, H1 2014 50
Drug Addiction Therapeutics - Recent Pipeline Updates, H1 2014 89
Drug Addiction - Dormant Projects, H1 2014 102
Drug Addiction - Discontinued Products, H1 2014 103
List of Figures
Number of Products under Development for Drug Addiction, H1 2014 11
Number of Products under Development for Drug Addiction - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 39
Assessment by Combination Products, H1 2014 40
Number of Products by Top 10 Target, H1 2014 41
Number of Products by Stage and Top 10 Target, H1 2014 42
Number of Products by Top 10 Mechanism of Action, H1 2014 44
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 45
Number of Products by Top 10 Route of Administration, H1 2014 47
Number of Products by Stage and Top 10 Route of Administration, H1 2014 48
Number of Products by Top 10 Molecule Type, H1 2014 49
Number of Products by Stage and Top 10 Molecule Type, H1 2014 50
